Guselkumab for crohn disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 19 Jan 2022: Trial registered, NCT05197049
  2. 19 Jan 2022: Trial started, NCT05197049

The trials

NCT03466411: A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

State
Under way
Phase
Phase 2 and Phase 3
People
1,409 taking part
Started
13 Apr 2018
Primary completion
20 Oct 2023
Arms
Phase 2 (GALAXI 1): Group 1 (Guselkumab), Phase 2 (GALAXI 1): Group 2 (Guselkumab), Phase 2 (GALAXI 1): Group 3 (Guselkumab), Phase 3 (GALAXI 2 and 3): Group 1 and Group 2 (Guselkumab)
Results
Posted on the registry
  1. 15 Mar 2018: Trial registered
  2. 13 Apr 2018: Trial started
  3. 7 May 2025: Trial results posted

NCT05197049: A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

State
Under way
Phase
Phase 3
People
350 taking part
Started
19 Jan 2022
Primary completion
4 Jul 2023
Arms
Group 1: Guselkumab, Group 2: Guselkumab
Results
Posted on the registry
  1. 19 Jan 2022: Trial registered
  2. 19 Jan 2022: Trial started
  3. 21 Feb 2025: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Guselkumab Dose 4, Guselkumab Dose 5, Tremfya.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.